2. Signaling Pathways
  3. Cell Cycle/DNA Damage
    Epigenetics
  4. PARP
  5. PARP4 Isoform

PARP4

PARP4 (poly(ADP-ribose) polymerase 4, also known as VPARP) is a member of the PARP family that catalyzes ADP-ribosylation and is predominantly associated with the vault ribonucleoprotein complex, linking it to cellular regulatory processes beyond canonical DNA damage sensing pathways[1][2]. Unlike PARP1 and several other DNA-dependent PARP family members, PARP4 lacks the N-terminal DNA-binding domain that directly activates catalytic activity upon DNA damage, indicating a distinct regulatory mechanism that may depend on protein-protein interactions mediated by its extensive C-terminal region[2][3]. Mechanistically, PARP family enzymes participate in ADP-ribosylation-dependent control of genomic stability, signal transduction, apoptosis, inflammatory regulation, and cellular stress responses, providing the broader biological context in which PARP4 functions are investigated[4][5]. In disease-related studies, PARP4 has been implicated in cancer biology and has been reported to protect against lung adenocarcinoma progression through regulation of RNA splicing via interaction with hnRNPM[6]. Experimental evidence further indicates that PARP4-deficient mice are viable and fertile under normal conditions but display increased susceptibility to chemically induced colon tumor formation, supporting a context-dependent role in tumor suppression[6]. Compared with related PARP isoforms that are established therapeutic targets, the biological functions of PARP4 remain less completely defined, and no PARP4-selective inhibitors have achieved comparable research or clinical utility, making mechanistic studies of this isoform an active area of investigation[4][5].

PARP4 Related Products (11):

Cat. No. Product Name Effect Purity
  • HY-10619
    Niraparib
    		Inhibitor 99.96%
    Niraparib (MK-4827) is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor with IC50s of 3.8 and 2.1 nM, respectively. Niraparib leads to inhibition of repair of DNA damage, activates apoptosis and shows anti-tumor activity.
  • HY-10619A
    Niraparib hydrochloride
    		Inhibitor 99.41%
    Niraparib hydrochloride (MK-4827 hydrochloride) is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor with IC50s of 3.8 and 2.1 nM, respectively. Niraparib hydrochloride leads to inhibition of repair of DNA damage, activates apoptosis and shows anti-tumor activity.
  • HY-136979
    RBN012759
    		Inhibitor 99.33%
    RBN012759 is a potent, selective and orally active inhibitor of PARP14, with an IC50 of <3 nM. RBN012759 displays 300-fold selectivity over the monoPARPs and 1000-fold selectivity over the polyPARPs. RBN012759 decreases pro-tumor macrophage function and elicits inflammatory responses in tumor explants.
  • HY-10619B
    Niraparib tosylate
    		Inhibitor 99.99%
    Niraparib tosylate (MK-4827 tosylate) is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor with an IC50 of 3.8 and 2.1 nM, respectively. Niraparib tosylate leads to inhibition of repair of DNA damage, activates apoptosis and shows anti-tumor activity.
  • HY-148566
    OUL232
    		Inhibitor 99.86%
    OUL232 is a potent inhibitor of mono-ARTs PARP7, PARP10, PARP11, PARP12, PARP14, and PARP15. OUL232 is the most potent PARP10 inhibitor described to date (IC50=7.8 nM), as well as the first PARP12 inhibitor ever reported.
  • HY-150207
    RBN-3143
    		Inhibitor 99.29%
    RBN-3143 is a potent and NAD+-competitive catalytic PARP14 inhibitor with an IC50 value of 4 nM. RBN-3143 inhibits PARP14-mediated ADP-ribosylation and stabilizes PARP14 in cell lines. RBN-3143 can be used in research of lung inflammation.
  • HY-10619E
    Niraparib tosylate hydrate
    		Inhibitor 99.97%
    Niraparib (MK-4827) tosylate hydrate is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor with IC50s of 3.8 and 2.1 nM, respectively. Niraparib tosylate hydrate leads to inhibition of repair of DNA damage, activates apoptosis and shows anti-tumor activity.
  • HY-148754
    PARP10-IN-3
    		Inhibitor 98.72%
    PARP10-IN-3 is a selective mono‐ADP‐ribosyltransferase PARP10 inhibitor with an IC50 of 480 nM for human PARP10. PARP10-IN-3 reveals potent inhibition on PARP2 and PARP15 with IC50s of 1.7 μM for human PARP2 and human PARP15, respectively.
  • HY-148753
    PARP10-IN-2
    		Inhibitor 98.02%
    PARP10-IN-2 is a potent mono‐ADP‐ribosyltransferase PARP10 inhibitor with an IC50 of 3.64 μM for human PARP10. PARP10-IN-2 reveals potent inhibition on PARP2 and PARP15 with IC50s of 27 μM and 11 μM for human PARP2 and human PARP15, respectively.
  • HY-155993
    YCH1899
    		Inhibitor 99.39%
    YCH1899 is an orally active PARP inhibitor, with an IC50< 0.001 nM for PARP1/2. YCH1899 exhibits distinct antiproliferation activity against Olaparib (HY-10162)-resistant and Talazoparib (HY-16106)-resistant Capan-1 cells (Capan-1/OP and Capan-1/TP cells) , with IC50 values of 0.89 and 1.13 nM, respectively. YCH1899 has acceptable pharmacokinetic properties in rats.
  • HY-W294889
    OUL245
    		Inhibitor
    OUL245 is a 7-Hydroxy derivative, and a selectively PARP2 inhibitor (IC50=44 nM). OUL245 also inhibits other PARP and TNKS enzymes with IC50s of 2.9-8.8 μM.